RAPT Therapeutics, Inc. Common Stock
RAPTRAPT Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for cancer and inflammatory diseases. Leveraging its expertise in immunology and small-molecule drug discovery, RAPT aims to modulate immune cell activity to enhance treatment outcomes.
Company News
Rapt Therapeutics shares surged 64% after British pharmaceutical giant GSK agreed to acquire the biotech company for $2.2 billion, or $58 per share. The deal grants GSK global rights to ozureprubart, Rapt's experimental antibody therapy currently in phase 2 trials designed to treat severe food allergies affecting over 1.3 million people in the U.S.
Monteverde & Associates PC, a class action securities firm, has announced an investigation into RAPT Therapeutics' proposed acquisition by GSK plc. Under the deal terms, RAPT shareholders are expected to receive $58.00 per share in cash. The firm is investigating whether the transaction represents a fair deal for shareholders.
GSK has agreed to acquire RAPT Therapeutics for $2.2 billion, marking the second exit for Forbion Growth Fund III. RAPT's lead candidate ozureprubart is a long-acting monoclonal antibody for severe allergic diseases currently in late-stage clinical development. The transaction is expected to close in Q1 2026.
GSK agreed to acquire RAPT Therapeutics for $58.00 per share ($2.2 billion equity value) to gain ozureprubart, a long-acting anti-IgE monoclonal antibody in phase 2b development for food allergy protection. The drug offers potential quarterly dosing versus current bi-weekly injections. Concurrently, Pfizer is exiting its 11.7% stake in ViiV Healt...
The food allergy market is expected to grow significantly by 2034, driven by emerging therapies, increased diagnoses, and rising treatment costs. The market was valued at USD 3 billion in 2024, with the US accounting for approximately 79% of the total market.
